TG THERAPEUTICS, INC. (TGTX) Form 8-K — Nov 9, 2026
TG Therapeutics beat its stride in Q3 2026, posting $259.9 million in total revenue — up roughly 61% year over year — including $232.6 million of BRIUMVI U.S. net product revenue, a ~52% increase over Q3 2025. The company raised full-year 2026 guidance to approximately $1 billion in global revenue from ~$950 million, and now expects $915-920 million in BRIUMVI U.S. net product revenue.
Key figures
- Eps
- Basic $0.39 / Diluted $0.35 for Q3 2026
- Revenue
- 259936000
- Guidance
- Full-year 2026 total global revenue raised to approximately $1 billion (from ~$950M); BRIUMVI U.S. net product revenue raised to $915-920 million (from $890-905M); FY2026 opex (R&D + SG&A ex non-cash comp) reaffirmed at $450-500 million
- Net Income
- 55463000
- Revenue Yoy
- approximately 61% increase vs. Q3 2025 total revenue of $161.7 million
- Total Assets
- 1592252000
- Cash Position
- 556709000
- Shares Outstanding
- 140,786,274 weighted-average basic shares Q3 2026
- Buyback q3 2026
- $100 million / ~2.0 million shares at average $49.43
- Ultimate 7yr arr
- 0.018
- Buyback cumulative
- $300 million / 8.9 million shares (~6% of shares outstanding) at average $33.88
- Sga expense q3 2026
- 80668000
- R and d expense q3 2026
- 51290000
- Operating income q3 2026
- 85899000
- Prior year q3 tax benefit
- 365000000
- Product revenue net 9m 2026
- 677145000
- Product revenue net q3 2026
- 240043000
- Enable real world relapse free
- 99.2% (1,076 participants)
- Subq briumvi phase3 data timing
- year-end 2026 or early 2027
- Briumvi us net product revenue q3 2026
- 232600000
- Briumvi us net product revenue yoy growth
- approximately 52%
- License milestone royalty revenue q3 2026
- 19893000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.